首页> 外文OA文献 >Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

【2h】

Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

机译：根据美国国家监测数据得出的病原体分布，ceftolozane /他唑巴坦加甲硝唑与哌拉西林/他唑巴坦作为治疗复杂腹腔感染的初步经验疗法的成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Vimalanand S. Prabhu; Joseph S. Solomkin; Goran Medic; Jason Foo; Rebekah H. Borse; Teresa Kauf; Benjamin Miller; Shuvayu S. Sen; Anirban Basu;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States [J] . Vimalanand S. Prabhu, Joseph S. Solomkin, Goran Medic, Antimicrobial Resistance and Infection Control . 2017,第1期

机译：根据美国国家监测数据得出的病原体分布情况，头孢洛赞/他唑巴坦联合甲硝唑与哌拉西林/他唑巴坦作为初始经验疗法治疗复杂腹腔内感染的成本效益
2. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections [J] . Teresa L Kauf, Vimalanand S. Prabhu, Goran Medic, BMC Infectious Diseases . 2017,第1期

机译：头孢洛赞/他唑巴坦与哌拉西林/他唑巴坦相比作为体外治疗的经验疗法的成本效益是基于美国细菌分离物的体外监测，用于治疗复杂的尿路感染
3. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections [J] . Teresa L Kauf, Vimalanand S. Prabhu, Goran Medic, BMC Infectious Diseases . 2017,第1期

机译：头孢洛赞/他唑巴坦与哌拉西林/他唑巴坦相比作为体外治疗的经验疗法的成本效益是基于美国细菌分离物的体外监测，用于治疗复杂的尿路感染
4. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States [O] . Vimalanand S. Prabhu, Joseph S. Solomkin, Goran Medic, 2017

机译：根据美国国家监测数据得出的病原体分布情况头孢洛赞/他唑巴坦联合甲硝唑与哌拉西林/他唑巴坦作为初始经验疗法治疗复杂腹腔内感染的成本效益
5. Cost-Effectiveness of Ceftolozane/Tazobactam Plus Metronidazole as Empiric Therapy for the Treatment of Complicated Intra-Abdominal Infections in Colombia [O] . P Lasalvia, D Rosselli, C Castañeda-Cardona, 2018

机译：Ceftolozane / Tazobactam Plus甲硝唑的成本效果作为牙龈复杂内感染复杂的腹腔内感染的验证疗法

Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

著录项

相似文献

相关主题

期刊订阅